The UK and US have signed a landmark commercial pact that will guarantee zero tariffs on British drug exports going into the American market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has pledged to raise funding on drugs through the NHS. This commitment ensures that import taxes on these key products will stay at nothing for a duration of the next three years.
This development comes after recent warnings to dramatically increase tariffs on branded drug imports, with potential rates discussed reaching double the cost.
"This arrangement with the United Kingdom strengthens the worldwide climate for cutting-edge drugs and establishes long-overdue fairness to American-British pharmaceutical trade," a release declared.
Economic Importance
Medicines represent one of the Britain's largest goods shipped to the United States, which is easily the biggest destination for major companies like GSK and AstraZeneca.
Export figures show that in the one-year period prior to last September, the UK shipped medicines worth billions to the US. This figure accounted for 17.4% of British export trade in that timeframe.
"This deal secures work, stimulates funding and paves the way for the UK to establish itself as a international leader for biotech and pharma," a minister stated.
Detailed British Pledges
The deal includes several specific commitments from the British government:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it considers new treatments to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a goal to increase overall public funding on medicines from 0.3% of Gross Domestic Product to 0.6% over the following ten-year period.
- Rebate Cap: The amount pharmaceutical firms must refund to the NHS to stay within budget will be restricted at 15%. In the past, rebates topped 20%.
Recent Tensions
The pact takes place against a protracted tension between the pharmaceutical industry and the ministers over medicine costs and approval rates.
This friction were exacerbated by arguments that US patients were paying a premium for the identical medicines than consumers in the other developed nations.
Recently, several large pharmaceutical investments in the UK have been delayed or cancelled, while multi-billion-dollar expansions have been directed toward American operations.
The Science Minister publicly accepted that the NHS must increase expenditure on medicines, noting that its expenditure on drugs had declined as a percentage of its total funding over the past decade.
